Literature DB >> 20389017

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

Ken-ichi Matsuoka1, Haesook T Kim, Sean McDonough, Gregory Bascug, Ben Warshauer, John Koreth, Corey Cutler, Vincent T Ho, Edwin P Alyea, Joseph H Antin, Robert J Soiffer, Jerome Ritz.   

Abstract

CD4+CD25+Foxp3+ Tregs have an indispensable role in the maintenance of tolerance after allogeneic HSC transplantation (HSCT). Patients with chronic graft-versus-host disease (GVHD) have fewer circulating Tregs, but the mechanisms that lead to this deficiency of Tregs after HSCT are not known. Here, we analyzed reconstitution of Tregs and conventional CD4+ T cells (Tcons) in patients who underwent allogeneic HSCT after myeloablative conditioning. Following transplant, thymic generation of naive Tregs was markedly impaired, and reconstituting Tregs had a predominantly activated/memory phenotype. In response to CD4+ lymphopenia after HSCT, Tregs underwent higher levels of proliferation than Tcons, but Tregs undergoing homeostatic proliferation also showed increased susceptibility to Fas-mediated apoptosis. Prospective monitoring of CD4+ T cell subsets revealed that Tregs rapidly expanded and achieved normal levels by 9 months after HSCT, but Treg levels subsequently declined in patients with prolonged CD4+ lymphopenia. This resulted in a relative deficiency of Tregs, which was associated with a high incidence of extensive chronic GVHD. These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389017      PMCID: PMC2860902          DOI: 10.1172/JCI41072

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  79 in total

1.  Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation.

Authors:  S Onder Alpdogan; Sydney X Lu; Neel Patel; Suzanne McGoldrick; David Suh; Tulin Budak-Alpdogan; Odette M Smith; Jeremy Grubin; Christopher King; Gabrielle L Goldberg; Vanessa M Hubbard; Adam A Kochman; Marcel R M van den Brink
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 2.  Generation and maintenance of memory CD4(+) T Cells.

Authors:  Ester M M van Leeuwen; Jonathan Sprent; Charles D Surh
Journal:  Curr Opin Immunol       Date:  2009-03-11       Impact factor: 7.486

Review 3.  Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets.

Authors:  Siegfried Kohler; Andreas Thiel
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

4.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

Authors:  Debora Franceschini; Marino Paroli; Vittorio Francavilla; Melissa Videtta; Stefania Morrone; Giancarlo Labbadia; Antonella Cerino; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

Review 5.  Homeostasis of naive and memory T cells.

Authors:  Charles D Surh; Jonathan Sprent
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

6.  Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.

Authors:  Emmanuel Zorn; Mehrdad Mohseni; Haesook Kim; Fabrice Porcheray; Allison Lynch; Roberto Bellucci; Christine Canning; Edwin P Alyea; Robert J Soiffer; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

7.  Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions.

Authors:  Cecile Le Saout; Sandie Mennechet; Naomi Taylor; Javier Hernandez
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

8.  In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease.

Authors:  Dongchang Zhao; Chunyan Zhang; Tangsheng Yi; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-06-12       Impact factor: 22.113

9.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

10.  Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells.

Authors:  Martin Guimond; Rachelle G Veenstra; David J Grindler; Hua Zhang; Yongzhi Cui; Ryan D Murphy; Su Young Kim; Risu Na; Lothar Hennighausen; Sema Kurtulus; Batu Erman; Polly Matzinger; Melinda S Merchant; Crystal L Mackall
Journal:  Nat Immunol       Date:  2009-01-11       Impact factor: 25.606

View more
  111 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

2.  Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease.

Authors:  Hemalatha Rangarajan; Maryam Yassai; Hariharan Subramanian; Richard Komorowski; Megan Whitaker; Jack Gorski; William R Drobyski
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

3.  Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.

Authors:  S Haji; J Kiyasu; I Choi; Y Suehiro; K Toyoda; M Tsuda; A Takamatsu; Y Nakashima; H Miyoshi; M Shiratsuchi; S Yamasaki; N Uike; Y Abe
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

4.  Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Authors:  Sawa Ito; Catherine M Bollard; Mattias Carlsten; Jan Joseph Melenhorst; Angélique Biancotto; Ena Wang; Jinguo Chen; Yuri Kotliarov; Foo Cheung; Zhi Xie; Francesco Marincola; Kazushi Tanimoto; Minoo Battiwalla; Matthew J Olnes; Shira Perl; Paula Schum; Thomas E Hughes; Keyvan Keyvanfar; Nancy Hensel; Pawel Muranski; Neal S Young; A John Barrett
Journal:  Mol Ther       Date:  2014-04-01       Impact factor: 11.454

5.  Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Authors:  Roger Belizaire; Haesook T Kim; Samuel J Poryanda; Nikola V Mirkovic; Evelyn Hipolito; William J Savage; Carol G Reynolds; Marie J Fields; Jennifer Whangbo; Tomohiro Kubo; Sarah Nikiforow; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Bruce R Blazar; Joseph H Antin; Jerome Ritz; Robert J Soiffer; John Koreth
Journal:  Blood Adv       Date:  2019-04-09

6.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

7.  Tregs, HSCT, and acute GVHD: up close and personal.

Authors:  John Koreth; Jerome Ritz
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

8.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

9.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

10.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.